Avadim Health Inc. ahi postponed a planned initial public offering on Thursday that would have seen the developer of non-prescription topical antiseptics raise up to $75 million, according to Renaissance Capital, a provider of institutional research and IPO exchange-traded funds. The Asheville, North Carolina-based company had filed to sell 5 million shares priced at $14 to $16 each before Thursday’s news.